This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Paragon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
by Zacks Equity Research
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
Paragon 28, Inc. (FNA) Moves 16.2% Higher: Will This Strength Last?
by Zacks Equity Research
Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sensus Healthcare, Inc. (SRTS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 116.67% and 3.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28 (FNA) BEAST Cortical Fibers Launch Boosts Biologics
by Zacks Equity Research
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Paragon 28 (FNA) New Staple System Expands Ankle Device Line
by Zacks Equity Research
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Paragon 28, Inc. (FNA) Surges 12.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paragon 28, Inc. (FNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -44.44% and 2.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of 1.75% and 9.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -10% and 3.53%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.36% and 6.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Paragon 28, Inc. (FNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -45.45% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Paragon 28, Inc. (FNA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Paragon 28, Inc. (FNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 34%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 33.5% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is EDAP TMS (EDAP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Paragon 28, Inc. (FNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of 0% and 8.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of -0.50% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 200% and 8.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aileron Therapeutics, Inc. (ALRN) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Can Paragon 28, Inc. (FNA) Climb 63% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 63.3% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Paragon 28, Inc. (FNA) Upgraded to Buy: Here's Why
by Zacks Equity Research
Paragon 28, Inc. (FNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 64%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 63.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Paragon 28, Inc. (FNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Paragon 28, Inc. (FNA) and Gamida Cell (GMDA) have performed compared to their sector so far this year.